Cochrane · systematic review · CD015045
Colchicine for the treatment of COVID‐19
Mikolajewska, A, Fischer, A-L, Piechotta, V, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
9
No studies
4
Included studies
NR
No studies 4 · 30.8%Ungraded 0 · 0%Very low 2 · 15.4%Low 2 · 15.4%Moderate 5 · 38.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Colchicine plus standard care compared to standard care (plus/minus placebo) for hospitalised patients with COVID‐19 and moderate to severe disease
Population: people with COVID‐19 and moderate to severe disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality assessed up to day 28 Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | 2 studies · 11445 participants | Moderate Downgraded: risk of bias |
Worsening of clinical status: participants with clinical deterioration, defined as new need for invasive mechanical ventilation or death up to day 28 Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | 2 studies · 10916 participants | Moderate Downgraded: risk of bias |
Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | 1 study · 11340 participants | Moderate Downgraded: risk of bias |
Quality of life, including fatigue and neurological status at longest Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | NR | No studies |
Adverse events ( Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | 1 study · 72 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events ( Colchicine plus standard care vs standard care (plus/minus placebo) | no estimate extracted | 1 study · 105 participants | Very low Downgraded: risk of bias, imprecision |
Colchicine compared to placebo or standard care alone for non‐hospitalised patients with asymptomatic SARS‐CoV‐2 infection or mild COVID‐19
Population: people with SARS‐CoV‐2 infection and asymptomatic or mild disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality up to day 28 Colchicine vs placebo or standard care alone | no estimate extracted | 1 study · 4488 participants | Low Downgraded: imprecision |
Admission to hospital or death within 28 days Colchicine vs placebo or standard care alone | no estimate extracted | 1 study · 4488 participants | Moderate Downgraded: imprecision |
Symptom resolution Colchicine vs placebo or standard care alone | no estimate extracted | NR | No studies |
Duration to symptom resolution Colchicine vs placebo or standard care alone | no estimate extracted | NR | No studies |
Quality of life Colchicine vs placebo or standard care alone | no estimate extracted | NR | No studies |
Adverse events within 28 days Colchicine vs placebo or standard care alone | no estimate extracted | 1 study · 4412 participants | Low Downgraded: indirectness |
Serious adverse events within 28 days Colchicine vs placebo or standard care alone | no estimate extracted | 1 study · 4412 participants | Moderate Downgraded: imprecision |